Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Capital Expenditures: 2021-2024

Historic Capital Expenditures for SAB Biotherapeutics (SABS) over the last 4 years, with Dec 2024 value amounting to $55,377.

  • SAB Biotherapeutics' Capital Expenditures fell 18.40% to $55,377 in Q4 2024 from the same period last year, while for Dec 2024 it was $337,262, marking a year-over-year increase of 71.07%. This contributed to the annual value of $337,262 for FY2024, which is 71.07% up from last year.
  • According to the latest figures from Q4 2024, SAB Biotherapeutics' Capital Expenditures is $55,377, which was down 44.79% from $100,300 recorded in Q3 2024.
  • SAB Biotherapeutics' Capital Expenditures' 5-year high stood at $3.5 million during Q2 2021, with a 5-year trough of $21,300 in Q1 2023.
  • Moreover, its 3-year median value for Capital Expenditures was $81,905 (2022), whereas its average is $225,069.
  • In the last 5 years, SAB Biotherapeutics' Capital Expenditures slumped by 98.43% in 2023 and then skyrocketed by 505.98% in 2024.
  • Over the past 4 years, SAB Biotherapeutics' Capital Expenditures (Quarterly) stood at $2.4 million in 2021, then tumbled by 95.01% to $117,754 in 2022, then tumbled by 42.37% to $67,864 in 2023, then decreased by 18.40% to $55,377 in 2024.
  • Its Capital Expenditures was $55,377 in Q4 2024, compared to $100,300 in Q3 2024 and $52,511 in Q2 2024.